Black Diamond Therapeutics (BDTX) Earnings Date & Reports

Key Takeaways

• Black Diamond Therapeutics (BDTX) is expected to report third quarter 2026 results in early November, covering the three months ended September 30, 2026.
• Wall Street consensus calls for a net loss of roughly $0.06 per share, compared with a loss of $0.15 per share in the same quarter a year earlier.
• The company has beaten consensus EPS (earnings per share) estimates in eight consecutive quarters, according to MarketBeat.
• As a clinical-stage biotech, BDTX has no product revenue, so investor attention centers on spending discipline and the cash runway rather than sales.
• Lead program silevertinib is advancing through Phase 2 testing in frontline non-small cell lung cancer (NSCLC), with updated data serving as a major upcoming catalyst.
• For more context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Looking for AI-driven trade ideas? Discover Trending AI Robots to see how automated strategies are scanning the market right now.

Earnings Context and Why It Matters

Black Diamond Therapeutics is a clinical-stage oncology company developing "MasterKey" therapies designed to target families of oncogenic mutations in cancer. Because it generates no meaningful product revenue, its quarterly results matter less as a measure of sales and more as a window into operating costs, balance-sheet strength, and progress toward clinical milestones. Investors pay close attention to research and development (R&D) spending and the company's cash runway, which determines how long it can fund trials without raising additional capital. The upcoming report also lands as management prepares to share updated data from the Phase 2 trial of silevertinib in newly diagnosed lung cancer patients, making this earnings event a potential sentiment driver for the stock.

Earnings Expectations

Analysts expect Black Diamond Therapeutics to report a net loss of approximately $0.06 per share for the third quarter of 2026, according to MarketBeat, with consensus revenue near $8.33 million. The revenue figure is expected to reflect collaboration or out-licensing recognition rather than product sales. For comparison, the company posted a loss of $0.15 per share in the third quarter of 2025.

BDTX has a strong track record of beating consensus: it reported a loss of $0.17 per share in the second quarter of 2026 versus a $0.20 estimate, and MarketBeat notes it has topped EPS expectations in eight consecutive quarters. Still, estimates vary across data providers, with some sources projecting a loss closer to $0.03 to $0.10 per share. Given the lack of recurring revenue, investors will likely focus less on the headline EPS and more on cash burn, cash position, and any commentary on the silevertinib program.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. For those monitoring clinical-stage biotechs like BDTX, the screener can help surface trade ideas, trending stocks, and breakout candidates more efficiently than manual screening. Explore the AI Screener to build a watchlist aligned with your own strategy.

Market Reaction and Investor Sentiment

Sentiment heading into this report is shaped by the stock's clinical catalysts more than its financials. Black Diamond Therapeutics has posted narrow losses in recent quarters, with second quarter 2026 results highlighting a central nervous system (CNS) objective response rate (ORR) of 86% for silevertinib in frontline NSCLC patients with non-classical EGFR (epidermal growth factor receptor) mutations. That encouraging readout has kept analyst attention focused on the drug's regulatory path.

Key risk factors ahead of earnings include the timing and detail of upcoming data disclosures, any increase in R&D spending as trials expand, and the possibility of future financing or partnership decisions. Because the company remains pre-revenue, the stock can be sensitive to any shifts in cash runway guidance or clinical timelines rather than to the quarterly loss itself.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should watch how management frames the silevertinib program. The company has signaled plans to seek feedback from the U.S. Food and Drug Administration (FDA) on a potential registrational path in frontline EGFR-mutant NSCLC, and updated Phase 2 data — including ORR and preliminary duration of treatment — remain a key catalyst.

Cash runway is another focal point. Black Diamond Therapeutics reported cash and investments of $135.5 million as of September 30, 2025, and subsequent updates indicated a cash position around $110 million with runway extending into 2028. A longer runway gives the company flexibility to complete trials without immediate dilution, while any acceleration in spending could pressure that timeline.

Finally, monitor partnership developments. Management has expressed interest in exploring collaboration opportunities in NSCLC and glioblastoma (GBM) to advance silevertinib into later-stage development. Any commentary on partnering, trial enrollment, or cost trends will likely carry more weight for the stock than the quarterly earnings figure itself. As always, the outlook should be read in the context of clinical-stage biotech risk, where trial outcomes remain inherently uncertain.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations